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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine “Are antibiotics, other
than roxithromycin, an effective way to manage joint pain in rheumatoid arthritis?”
STUDY DESIGN: Review of three double-blind, randomized-controlled studies published in
English between 2001-2007.
DATA SOURCES: Three randomized controlled trials published between 2001 and 2007 were
found using PubMed/MEDLINE and Cochrane databases.
OUTCOMES MEASURED: Clinical outcome for all three studies used American College of
Rheumatology (ACR) criteria, which assesses joints for swelling and tenderness.
RESULTS: In the Odell et al.1 study, at 24 months 28 participants did meet the ACR50 criteria.
In treatment group 1, 18 of 30 (60%) participants and 10 of 30 (33%) participants in treatment
group 2 met the ACR50 criteria, (P=0.04). Ogrendik et al.2 34% of participants in the antibiotic
treatment group had an ACR50 response at 6 months versus 10% in treatment group 2. Ogrendik
et al.3 found that 34.2% of participants in the antibiotic treatment group had an ACR50 response
at 6 months compared to 7.9% in treatment group 2.
CONCLUSIONS: The statistical results from all three studies found that antibiotics had greater
efficacy in treating pain in rheumatoid arthritis compared to other interventions or placebo. It
would be beneficial to study the effects of antibiotic use in patients who had chronic RA.
KEYWORDS: antibiotics, rheumatoid arthritis

INTRODUCTION
Rheumatoid arthritis is a chronic autoimmune disease that can potentially lead to
permanent disability.3 The disease process begins when immune cells begin to release chemicals
that target the synovium and destroy cartilage and bone. The destruction of cartilage leads to
joint stiffness, tenderness, swelling, and limited mobility. While RA particularly affects the
smaller joints of the hands and wrist, it can also affect other joints and organs in more advanced
stages of the disease process.7 This paper evaluates three double-blind, randomized controlled
studies that look at the effectiveness of antibiotics, other than roxithromycin, in the management
of joint pain in RA.
RA is a serious autoimmune disease that can progress to permanent destruction and
limited mobility of certain joints, especially in the hands and wrists.6 RA affects approximately
one million Americans, 75% of those being women.7 The incidence of RA in the United States
has significantly decreased since the 1960s, but it continues to be the most common type of
autoimmune arthritis.8 Women are affected in the 4th and 5th decades, whereas men are affected
later in the 5th and 6th decades. In 2013, approximately $19 billion was spent on RA treatment
(medications, hospitalizations, office visits, and physical therapy), which amounts to about
$30,000 a year per patient. The costs for RA treatment is expected to increase over the next 4
years due to the development of new medications; newer medications mean increased costs.6 Per
2007 data, 2.6 million annual doctor’s visits were attributed to RA, and 2012 data showed
approximately 9,100 RA related hospitalizations.9
The exact etiology of RA is unknown. However, there are many risk factors and
comorbidities that are associated with RA. It is thought that a combination of environmental and
genetic factors contributes to the incidence of RA. Modifiable risk factors include: smoking, oral

contraceptives, hormone replacement therapy, breastfeeding, and irregular menses. Nonmodifiable risk factors include: genotypes HLA-DR4 and DRB1, age (40-60s), and sex
(female).9 There are also several comorbidities associated with RA. Though the exact correlation
between cardiovascular disease and RA is not fully understood, research has shown that with
further progression of RA the higher the prevalence of CVD. Also, infections, such as
tuberculosis, are also closely associated with RA.9 Data has shown up to ¼ of deaths in RA
patients are related to infections. Researchers are unsure if the infections associated with RA are
due to immune system failure or immunosuppressant used for treatment.9
Synthetic disease modifying antirheumatic drugs (DMARD) are the initial drug of choice
for RA, specifically methotrexate. Other synthetic DMARDs include sulfasalazine, leflunomide,
tofactinib, and hydroxychloroquine.4 There are also biological DMARDs used in the treatment of
RA, which include: TNF inhibitors, abatacept, rituximab, and tocilizumab. Typically, DMARDs
are most effective when used in combination with each other. The most common combination is
methotrexate and a TNF inhibitor.4 Low dose corticosteroids are also used for 2-6 weeks until
the biologic DMARD reaches its full efficacy.4 Combination DMARDs are currently the
standard of care. Antibiotic treatment, alone or in combination with a DMARD, has been
researched to determine their effectiveness at managing painful joints when used in early RA.
OBJECTIVE
The objective of this selective EBM review is to determine “Are antibiotics, other than
roxithromycin, an effective way to manage joint pain in rheumatoid arthritis?”
METHODS
Participants in the 3 double-blinded randomized controlled studies reviewed for this
paper included male/female adults who fulfilled American College of Rheumatology criteria. All

3 studies evaluated participants based on ACR criteria. Participants in the O’Dell et al.1 study
met the following criteria:19-70 years old, positive rheumatoid factor, duration of disease > 6
weeks to <1 year, and active RA (ESR 28 mm/hr, morning stiffness >45 minutes, >8 tender
joints, >3 swollen joints). Ogrendik et al.2 conducted a study with participants meeting the
following criteria: 18-70 years old, disease duration less than 3 years, failed DMARD therapy
(azathioprine, methotrexate, sulfasalazine, penicillamine, hydroxychloroquine, or injectable
gold), active disease at enrollment (12+ tender joints, 10+ swollen joints) and one of the
following ESR 28mm/hr, CRP > 2.0 mg/dl, or morning stiffness > 45 minutes. Ogrendik et al.3
conducted a study with participants meeting the following criteria: currently taking methotrexate
for at least 6 months, active disease (12+ tender joints, 10+ swollen joints), and at least one of
the following: ESR >28 mm/hr or CRP 2.0 mg/dl.
Interventions used in the above studies were: combination Minocycline 100 mg PO BID
x 2 years and low dose prednisone (7.5mg or 5 mg per day) versus combination
hydroxychloroquine 200 mg PO BID and low dose prednisone (O’dell et al.1), clarithromycin
500 mg PO QD x 6 months versus placebo (Ogrendik et al. 2), and levofloxacin 500 mg PO QD
x 6 months in combination with a stable dose of methotrexate either oral or subcutaneous versus
placebo plus stable dose of methotrexate (Ogrendik et al.3). The primary outcome measured for
all three studies was the reduction in the number of painful/tender joints after the appropriate
intervention was administered.
The clinical studies reviewed for this paper were found using Pubmed and Cochrane
Database. All sources were peer-reviewed articles printed in English between 2001-2007, and
keyword searches included: rheumatoid arthritis, minocycline, and antibiotics. Inclusion criteria
for this paper were randomized controlled trials, double blinded trials, all of which focused on

POEMs. The following were exclusion criteria for this paper: articles reviewing roxithromycin in
the treatment of RA, peer-reviewed articles published prior to 2000, Cochrane systematic
reviews, as well as previously published systematic reviews by former students. Statistics used in
all three studies include: control event rate (CER), experimental event rate (EER), relative
benefit increase (RBI), absolute benefit increase (ABI), number needed to treat (NNT) and pvalue. Table 1 (below) reports the demographics of each study used in this paper.

Table 1. Demographics & Characteristics of Included Studies
Study

Type

#pts

Age

O’dell,
2001 (1)

RCT

60

1970

Ogrendik
2007 (2)

RCT

81

1870

Ogrendik
2007 (3)

RCT

76

>18

Inclusion
Criteria
Pts who have had
RA for at least 6
weeks and fulfill
ACR criteria.

Pts who have
active disease,
defined as 12 or
more tender joints,
ten or more
swollen joints, and
at least 1 of the
following: SED
rate >28mm/h,
morning stiffness
>45mins, and
disease longer than
3 years.
Pts who had been
taking
methotrexate for at
least 6 months,
active disease, 12+
tender joints.

Exclusion
Criteria
Pts who received
previous disease
modifying drugs,
who received
steroids in the last
2 months, and
women of
childbearing age
who were not on
contraception.

W/D

Pregnant women,
elevated LFT and
RFT, chronic
infection, and
allergic to ABX
used in the study.

9

Pregnancy, serious
infection,
inadequate control
of arthritis
symptoms,
impaired LFT and
RFT, untreated
HTN.

6

5

Intervention
Minocycline
100 mg BID vs.
Hydroxychloro
quine 200 mg
BID
*both groups
were on low
dose prednisone
7.5mg or
5mg/day
500 mg of
clarithromycin
vs placebo

500 mg
levofloxacin vs
placebo
*both groups
were given
methotrexate
15-25mg/week

OUTCOMES MEASURED
The American College of Rheumatology (ACR) response is used in all three studies to
assess the efficacy of the intervention. ACR response include the following criteria:
tender/swollen joint count, acute phase reactant (such as sedimentation rate), patient assessment,
physician assessment, VAS pain score, and disability/functional questionnaire. ACR 20, 50, and
70 response were assessed in all three studies. This means that a person must have improved by
20, 50, or 70% for the designated intervention to have been clinically effective. In the O’Dell et.
al1 study, the intervention was minocycline 100 mg PO BID x 2 years plus low dose prednisone.
Ogrendik et al.2,3 studies also measure ACR20, ACR50, and ACR70; interventions used in these
two studies were Clarithromycin 500 mg PO QD x 6 months and Levofloxacin 500 mg PO QD x
6 months plus methotrexate 15-25 mg daily, respectively. The ACR criteria were assessed using:
Ritchie Articular Index, patient’s global assessment of disease activity with visual analog scale,
pain assessed with visual analog scale, physician’s global assessment of disease activity, and
Health Assessment Questionnaire (HAQ). The statistics reported or used in the articles were
relative benefit increase (RBI), absolute benefit increase (ABI), numbers needed to treat (NNT),
and P values.
RESULTS
All three studies looked at the efficacy of antibiotic treatment for pain management in
rheumatoid arthritis. Two studies compared the use of antibiotic treatment versus placebo, and
the third study compared antibiotic treatment to hydroxychloroquine.
The double-blinded RCT by O’Dell et al.1 further detailed in Table 1, enrolled 60
participants. Patients who had previously taken DMARDs, steroid therapy in the last 2 months,
or women of childbearing age were excluded from this study.1 60 participants were randomly

assigned to treatment group 1 or 2. Treatment group 1 refers to the minocycline intervention (100
mg BID), and treatment group 2 refers to the hydroxychloroquine intervention (200 mg BID).
Both treatment groups were started on prednisone 7.5mg/day or 5mg/day if they weighed <60kg
and tapered down if they met ACR50 criteria at 12 months. ACR50 criteria was assessed using
patient’s assessment of disease activity, physician’s global assessment of disease activity, tender
joint and swollen joint count, HAQ, erythrocyte sedimentation rate, and patient’s assessment of
pain on 100-mm visual analog scale. Using the Ritchie Articular Index, 38 joints were assessed
for tenderness and swelling. At 24 months, 28 participants did meet the ACR50 criteria. In
treatment group 1, 18 of 30 (60%) participants and 10 of 30 (33%) participants in treatment
group 2 met the ACR50 criteria, (P=0.04). At the beginning of the study, participants in
treatment group 1 had an average of 18.9 tender joints and an average VAS pain score of 5.13.
At the completion of the study, those participants had an average of 6.8 tender joints and an
average VAS pain score of 2.5. Patient’s initial global assessment in treatment group 1 was 4.7
compared to 2.0 at 24 months. At 12 months, those who met ACR50 criteria began to taper off
prednisone. At the end of the 2-year study, prednisone dosages were also assessed and doses
were lower in treatment group 1 (0.81 mg/day) than treatment group 2 (3.21 mg/day), (P<0.01).
Also, participants in treatment group 1 were more likely to be completely tapered off prednisone
at 24 months, (P=0.03)1. 3 participants in treatment group 1 and 2 from treatment group 2
withdrew due to adverse reactions. Adverse reactions from treatment group 1 included:
fingernail discoloration, dizziness, and an erythematous rash, and in treatment group 2: reasons
for withdrawal were rash and gastrointestinal distress.
The 6-month randomized double-blind controlled study by Ogrendik et al.2 randomly
assigned 81 participants to either treatment group 1 (500 mg clarithromycin per day) or treatment

group 2 (placebo). Exclusion criteria for this study was the following: pregnant women, impaired
hepatic enzyme tests, impaired renal function, chronic/recurrent infection, or history of allergic
reactions to macrolides. Participants’ outcomes were assessed using the same criteria as Odell et
al.1 to determine if they met ACR 20 and 50 response, but for the purposes of this paper ACR50
response will be the focus. At the beginning of the study, treatment group 1 had an average of 30
tender joints and a VAS pain score of 6.9. After 6-months, the average tender joint count for
treatment group 1 was 11 and a VAS pain score of 3.2, (P<0.001). Table 2 shows more
participants in treatment group 1 (34%) had met ACR50 criteria after 6 months compared to
those in the placebo group (10%), (P<0.001). 9 participants withdrew from the study due to
unsatisfactory treatment/worsening of disease; 3 participants were from treatment group and 6
were from treatment group 2. In treatment group 1, the major complaint was a metallic taste or
dry mouth (46%), (P <0.001). Also, 10% of participants in treatment group 1 and 8% in
treatment group 2 complained of GI pain, (P<0.001). 17% of treatment group 1 and 15% of
treatment group 2 complained of headaches, (P<0.001).
In the 6-month randomized double-blind controlled study, Ogrendik et al.3 looked at the
efficacy of levofloxacin versus placebo. Exclusion criteria for this study was the following:
pregnancy, serious infection, inadequate control of arthritis, impaired renal function, untreated
HTN, other inflammatory diseases, and any other relevant systemic disease. 76 participants were
randomly assigned to treatment group 1 (500mg levofloxacin daily) or treatment group 2
(placebo). At baseline, treatment group 1 had an average tender joint count of 32 and a VAS pain
score of 6.5. At 6 months, treatment group 1 average tender joint count was 10 and VAS pain
score of 2.2, (P<0.001). Participants were assessed utilizing the same criteria as Ogrendik et al.2
ACR 50 response was assessed after 6 months to determine the efficacy of levofloxacin versus

placebo. At 6 months, treatment group 1 showed greater response per the ACR criteria. 5% of
participants in treatment group 1 and 11% from treatment group 2 withdrew due to unsatisfactory
response to their intervention. There were no serious adverse events reported in this study. The
more frequent complaint from treatment group 1 was gastrointestinal pain (15.6%) compared to
treatment group 2 (5.3%), (P=0.05). Other adverse events included: nausea, vomiting, diarrhea,
headache, and dry mouth. Overall, levofloxacin was well tolerated among participants.3
Table 2. Comparison of ACR50 Criteria Between Treatment Group 1 and 2
Study

ACR 50
Treatment Group 1
%
Antibiotic

P-value
Treatment Group 1

ACR 50
Treatment Group 2
%

P- value
Treatment Group 2

O’dell et al.1

60

p=0.04

33

p=0.04

Ogrendik et al.2

34

P<0.001

10

P<0.001

Ogrendik et al. 3

34.2

P<0.001

7.9

P<0.001

Table 3 details relative benefit increase (RBI), absolute benefit increase (ABI), numbers
needed to treat (NNT), and P values for each of the three studies used in this paper. P value
signifies the probability that the outcome was due to chance. If the p value was less than 0.5,
then it is unlikely the outcome was due to chance. All three studies had P values <0.5 (P=0.04,
<0.001, 0.001, respectively). Also, NNT ranged between 3 and 5, signifying the number of
patients that would need to be treated to prevent 1 adverse event.
Table 3. O’Dell study: v. Hydroxychloroquine
Study
O’dell et al.1
Ogrendik et al.2
Ogrendik et al.3

CER
HCQ
0.33
0.10
0.79

EER
minocycline
0.60
0.34
0.34

RBI

ABI

NNT

P value

0.82
2.4
2.14

0.27
0.24
0.40

4
5
3

P=0.04
P<0.001
P<0.001

DISCUSSION

In Odell et al.,1 combination minocycline and prednisone had more success in controlling
pain compared to combination hydroxychloroquine and prednisone. Minocycline is often used in
treatment of acne, cellulitis, as well as the treatment of RA. Contraindications to minocycline
include a previous allergic reaction or sensitivity to it. Adrenal suppression can be a possible side
effect of prednisone with long term use.4
Also, in Ogrendik et al.,2 clarithromycin had great efficacy in treating pain compared to
placebo. Clarithromycin is a broad spectrum antibiotic that is often used for the treatment of
upper respiratory infections, peptic ulcer disease, pneumonia, as well as skin infections. 4
Contraindications to this antibiotic include: concomitant use with HMG-CoA reductase
inhibitors (statins) or colchcine or in patients who are renally impaired.4
Statistical results from Ogrendik et al.3 study favored the use of levofloxacin. Black box
warnings for this antibiotic include; tendon rupture, CNS effects, and peripheral neuropathy. It
can also accentuate symptoms of myasthenia gravis. This fluoroquinolone is often used for
pneumonia, UTI, and pyelonephritis.5
Firstly, the sample size for each study was considerably small. The largest study included
81 participants and the smallest was 60. Also, in the study that investigated clarithromycin,
participants had an initial side effect of a metallic taste in their mouth. Researchers in this study
presumed that the blinding in the studied was compromised at this point, because they believed
that the taste was due to the antibiotic killing bacteria in the mouth.2 Also, GI side effects are
common in the use of antibiotics.5 Blinding may have been compromised for this reason after
researchers assessed for side effects throughout the study. Another limitation in 2 of the studies

was the use of combination treatment; for this reason it was difficult to determine the exact
efficacy of levofloxacin and minocycline.
CONCLUSION
This paper reviewed three double-blind randomized controlled studies that investigated
the significance of antibiotic use in the management of pain in rheumatoid arthritis. The
statistical results from all three studies found that antibiotics had greater efficacy in treating pain
in rheumatoid arthritis compared to other interventions or placebo. Other than increasing the
population size to increase the validity and reliability of antibiotic use in the management of pain
in RA, future studies should consider using a higher range for ESR and CRP cutoff. Using low
values would be associated with earlier stages of RA. However, it would be beneficial to study
the effects of antibiotic use in patients who had chronic RA. The treatment of RA with
antibiotics will hopefully be explored in the future alone or in combination with DMARDs.
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